M1411 HCPCS Reimbursement & Policy Benchmarks | OpenPayer

Summary & Overview

HCPCS M1411: First-Line Immune Checkpoint Inhibitor Without Chemotherapy

HCPCS Level II code M1411 identifies patients who are receiving first-line immune checkpoint inhibitor therapy without concurrent chemotherapy. This designation matters nationally as immune checkpoint inhibitors are a rapidly expanding class of cancer therapies with distinct utilization, billing, and care coordination implications across payers and sites of care. Accurate use of M1411 supports appropriate claims processing, utilization review, and outpatient oncology care workflows.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for first-line immune checkpoint inhibitor use, the typical outpatient infusion or clinic setting for these services, and the payer landscape relevant to coverage and claim adjudication. The publication outlines common billing considerations, benchmarking areas, and recent policy developments affecting immunotherapy coding and reimbursement. Where data is not available in the input, the report notes missing elements such as specific ICD-10 pairings, associated taxonomies, and related billing lines.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1411HCPCS Level IIimmunotherapyoncologyinfusionfirst-line therapyoutpatient carebillingcodingclaims

Billing Code Overview

HCPCS Level II code M1411 denotes patients who are currently on first-line immune checkpoint inhibitors without chemotherapy. This code is used to indicate that a patient is receiving cancer immunotherapy as the initial systemic treatment and that no concurrent cytotoxic chemotherapy is being administered.

Service type: Ongoing outpatient systemic immunotherapy management and monitoring
Typical site of service: Oncology outpatient clinic or infusion center

Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and specific service line.

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with metastatic non–small cell lung cancer (NSCLC) presents to the outpatient oncology infusion center for ongoing therapy. The patient has been started on first-line immune checkpoint inhibitor monotherapy (e.g., pembrolizumab or nivolumab) without concurrent cytotoxic chemotherapy based on tumor PD-L1 expression and ECOG performance status. Vital signs and laboratory review (CBC, CMP, thyroid function) are completed by nursing prior to infusion. The clinical workflow includes: pre-infusion assessment and verification of indication and consent, administration of the immune checkpoint inhibitor via intravenous infusion, adverse event monitoring during and after infusion (including management of immune-related adverse events), documentation of drug, dose, lot number, and start/stop times, and billing using the HCPCS Level II code M1411 to indicate the patient is currently on first-line immune checkpoint inhibitors without chemotherapy. Typical site of service is hospital outpatient infusion center or freestanding oncology infusion clinic. Common payors for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When additional and significant work beyond the typical infusion service is documented (e.g., extended infusion due to complex management).

HCPCS Level II M1372: Glycemic Status HbA1c 7.0–7.9%

HCPCS-M1399-PATIENT-LEFT-PRACTICE-DURING-FOLLOW-UP

HCPCS M1399: Patient Leaves Practice During Follow-Up

HCPCS-M1155-ANAPHYLAXIS-PNEUMOCOCCAL-VACCINE

HCPCS M1155: Anaphylaxis Due to Pneumococcal Vaccine, Documented

HCPCS-M1480-ASSESSMENT-VALIDITY-IMPACTED-BY-PATIENT-CAPACITY-OR-MOTIVATION

HCPCS M1480: Assessment Validity Impacted by Patient Capacity or Motivation

HCPCS-M1330-DOCUMENTATION-REASON-NO-FOLLOW-UP-EXAM

HCPCS Level II M1330: Documentation of Reason for No Follow-Up Exam

HCPCS-M1390-MELANOMA-RECURRENCE-EXAM-NOT-DOCUMENTED

HCPCS Level II M1390: Missing Exam for Melanoma Recurrence

HCPCS-M1185-IMMUNE-CHECKPOINT-INHIBITOR-THERAPY-NOT-HELD-OR-STEROIDS-NOT-DOCUMENTED

HCPCS M1185: Documentation of Immune Checkpoint Inhibitor/Corticosteroid Management Not Performed

HCPCS-M1195-SURGICAL-PATHOLOGY-REPORT-MMR-MSI-TESTING-NOT-STATED

HCPCS M1195: Surgical Pathology Report Missing MMR/MSI Impression or Recommendation

HCPCS-M1357-FOLLOW-UP-REDUCTION-IN-SUICIDAL-IDEATION-OR-BEHAVIOR

HCPCS Level II M1357: Reduction in Suicidal Ideation or Behavior

HCPCS-M1189-KIDNEY-HEALTH-EVALUATION-EGFR-UACR

HCPCS M1189: Kidney Health Evaluation with eGFR and UACR

Showing 1–10 of 356

Taxonomy Code	Specialty	Notes
`207Q00000X`	Medical Oncology	Primary specialty responsible for prescribing and overseeing immune checkpoint inhibitor therapy.
`208000000X`	Hematology & Oncology	Common combined specialty managing systemic cancer therapy including immunotherapy.
`363A00000X`	Infusion Therapy	Nursing or infusion specialists who administer and monitor IV biologic agents.
`362K00000X`	Oncology Nursing	Registered nurses providing direct infusion care, patient education, and toxicity monitoring.
`2086S0122X`	Oncology - Clinical Pharmacology	Oncology pharmacists involved in preparation, dosing verification, and dispensing of immune checkpoint inhibitors.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Represents non–small cell lung cancer patients who may receive first-line immune checkpoint inhibitor monotherapy without chemotherapy.
`C80.1`	Malignant (primary) neoplasm, unspecified	Used when a specific primary site is not documented but systemic therapy like immunotherapy is indicated.
`C77.1`	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Reflects metastatic spread for which first-line immunotherapy may be used.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Common metastatic site that can be present in patients receiving checkpoint inhibitors.
`Z51.11`	Encounter for antineoplastic chemotherapy	Used to indicate encounter for administration of systemic anticancer therapy such as immune checkpoint inhibitors.
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing long-term immunotherapy maintenance in the outpatient setting.
`D86.9`	Sarcoidosis, unspecified	Included as a relevant differential/contraindication screening diagnosis because granulomatous disease can affect immunotherapy risk assessment.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Used for administration of many IV oncology agents when infusion duration fits the code time; may be billed when infusion of checkpoint inhibitor meets time and documentation requirements.
`96415`	Chemotherapy administration, IV infusion; each additional hour (list separately in addition to code for primary infusion)	Billed when infusion lasts beyond the initial hour and additional time is documented for prolonged administration.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	May be used for initial IV biologic infusions when chemotherapy-specific codes are not appropriate per payer guidelines.
`96366`	Each additional hour (infusion), therapeutic/prophylactic/diagnostic	Used when infusion time extends beyond the first hour and is reportable per payer rules.
`96401`	Chemotherapy administration, IV push, single drug	Applicable for IV push administration of supportive drugs or pre-medications given with the immunotherapy infusion.
`96402`	Each additional single drug/biologic, IV push	Used when multiple IV push medications are administered during the visit.

OpenPayer